Skip to content
akaturk Academic measurement

Academician profile · PROFESÖR

YEŞİM AYDINOK

EGE ÜNİVERSİTESİ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Çocuk Hematolojisi ve Onkolojisi (Çocuk Sağlığı ve Hastalıkları)
  • TIP FAKÜLTESİ
  • DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Articles YÖKSİS 166
Projects 1
Books 17
Proceedings 42
Patents 1
Artistic 1
Scopus (SJR)
Q1 97 Q2 37 Q3 22 Q4 5
WoS (JCR)
Q1 72 Q2 27 Q3 29 Q4 36
TR Index 13 articles

Scopus (SJR)

WoS (JCR)

TR Index

13 articles

166 publications total

Articles

  1. 2026 Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary EXPERT REVIEW OF HEMATOLOGY DOI 10.1080/17474086.2025.2604524
  2. 2025 Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare? HemaSphere DOI 10.1002/hem3.70165
  3. 2025 Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study The Lancet Haematology DOI 10.1016/S2352-3026(25)00107-3
  4. 2025 Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary Expert Review of Hematology DOI 10.1080/17474086.2025.2604524
  5. 2025 Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial The Lancet DOI 10.1016/S0140-6736(25)00635-X
  6. 2025 Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare? HEMASPHERE DOI 10.1002/hem3.70165
  7. 2024 Identification of the molecular etiology in rare congenital hemolytic anemias using next‐generation sequencing with exome‐based copy number variant analysis European Journal of Haematology DOI 10.1111/ejh.14194
  8. 2024 Systematic literature review of the indirect costs and humanistic burden of β-thalassemia Therapeutic Advances in Hematology DOI 10.1177/20406207241270872
  9. 2024 Evaluation of the Effectiveness of Convalescent Plasma Therapy in Severe and Critical COVID-19 TURKISH JOURNAL OF INTENSIVE CARE-TURK YOGUN BAKIM DERGISI DOI 10.4274/tybd.galenos.2023.58815
  10. 2024 Identification of the molecular etiology in rare congenital hemolytic anemias using next-generation sequencing with exome-based copy number variant analysis EUROPEAN JOURNAL OF HAEMATOLOGY DOI 10.1111/ejh.14194
  11. 2023 Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study Ferrata Storti Foundation (Haematologica) DOI 10.3324/haematol.2023.283133
  12. 2023 Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years Ovid Technologies (Wolters Kluwer Health) DOI 10.1097/MPH.0000000000002723
  13. 2023 Highlights on the Luspatercept Treatment in Thalassemia MDPI AG DOI 10.3390/thalassrep13010008
  14. 2023 Combination chelation therapy Wiley DOI 10.1111/nyas.15052
  15. 2023 Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment INTERNATIONAL JOURNAL OF HEMATOLOGY DOI 10.1007/s12185-022-03497-4
  16. 2022 Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study. Ann Hematol. DOI 10.1007/s00277-021-04748-w
  17. 2022 Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study ANNALS OF HEMATOLOGY DOI 10.1007/s00277-021-04748-w
  18. 2022 An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results. Am J Hematol DOI 10.1002/ajh.26592
  19. 2022 Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment. Int J Hematol DOI 10.1007/s12185-022-03497-4
  20. 2022 Thalassaemia Lancet DOI 10.1016/S0140-6736(22)00536-0

Back to academicians